NIH-funded research R01 grant

IL-6 signaling and risk of postoperative cognitive decline in aging and Alzheimer’s disease

Official title: IL-6 Trans-signaling increases vulnerability to Postoperative Cognitive Decline in Aging and Alzheimers Disease

Funded at University of California, San Francisco · NIH-11336321 · Data updated 2026-11-12

This grant explores whether a specific inflammatory signal (IL-6) increases the chance of cognitive problems after surgery in older adults and those with Alzheimer’s disease, using aging and Alzheimer’s mouse models.

More Alzheimer's Disease research and trials

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUniversity of California, San Francisco
NIH-funded
Lab location1 site (San Francisco, United States)
Project startSeptember 15, 2024
Project endMay 31, 2029
Funding year2026
Award (this year)$1,071,467
NIH project number5R01AG083979-03
Project IDNIH-11336321 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates include adults aged 65 and older, especially those with Alzheimer’s disease or related dementias, who could potentially benefit from interventions identified in this research.

Less likely to help

The study is preclinical and will mainly use animal models; direct benefits to individual patients will depend on future clinical development.

What this research studies

The research aims to understand why some older patients, especially those with Alzheimer’s, develop cognitive changes after surgery. It will study IL-6 signaling in the brain and test whether blocking this signal with sgp130Fc can reduce vulnerability to postoperative cognitive problems. The team will use aging and Alzheimer’s mouse models to map where and how IL-6 trans-signaling affects memory-related brain circuits. Findings could point to a targeted approach to protect think skills during the perioperative period. The work combines neuroscience, immunology, and preclinical models to address a real-world patient risk.

Why it matters

Potential benefit: If successful, the work could lead to strategies that reduce postoperative cognitive issues in older adults and people with Alzheimer’s, improving recovery and long-term brain health.

How similar studies have gone: Prior work supports a link between IL-6 signaling and neuroinflammation and suggests potential for targeted blockade to mitigate cognitive effects, but translational success to perioperative settings remains exploratory.

Where this research is happening

  • University of California, San Francisco
    San Francisco, United States
    Active

Researchers

  • Principal investigator: Maze, Mervyn — University of California, San Francisco
  • Study coordinator: Maze, Mervyn

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.